| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 30/01/2025 | 11:45 | PR Newswire (US) | AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:AZN | AstraZeneca PLC |
| 28/01/2025 | 00:00 | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies | NASDAQ:AZN | AstraZeneca PLC |
| 27/01/2025 | 11:45 | PR Newswire (US) | Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN | NASDAQ:AZN | AstraZeneca PLC |
| 23/01/2025 | 20:33 | PR Newswire (Canada) | AstraZeneca prévoit un investissement de 820 M$ CA (570 M$ US) au Canada pour consolider son statut grandissant de plaque tournante mondiale et faire progresser la réalisation d'essais cliniques | NASDAQ:AZN | AstraZeneca PLC |
| 23/01/2025 | 20:32 | PR Newswire (Canada) | AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery | NASDAQ:AZN | AstraZeneca PLC |
| 23/01/2025 | 11:45 | PR Newswire (US) | AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN | NASDAQ:AZN | AstraZeneca PLC |
| 23/01/2025 | 11:00 | PR Newswire (US) | AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZN | NASDAQ:AZN | AstraZeneca PLC |
| 20/01/2025 | 11:45 | PR Newswire (US) | The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN | NASDAQ:AZN | AstraZeneca PLC |
| 17/01/2025 | 23:35 | Business Wire | DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer | NASDAQ:AZN | AstraZeneca PLC |
| 17/01/2025 | 13:00 | Business Wire | CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma | NASDAQ:AZN | AstraZeneca PLC |
| 16/01/2025 | 11:45 | PR Newswire (US) | Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZN | NASDAQ:AZN | AstraZeneca PLC |
| 13/01/2025 | 13:00 | Business Wire | Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer | NASDAQ:AZN | AstraZeneca PLC |
| 09/01/2025 | 11:45 | PR Newswire (US) | Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More | NASDAQ:AZN | AstraZeneca PLC |
| 02/01/2025 | 19:50 | PR Newswire (US) | AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN | NASDAQ:AZN | AstraZeneca PLC |
| 30/12/2024 | 11:45 | PR Newswire (US) | Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law Firm | NASDAQ:AZN | AstraZeneca PLC |
| 18/12/2024 | 15:05 | PR Newswire (Canada) | Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform n | NASDAQ:AZN | AstraZeneca PLC |
| 18/12/2024 | 15:05 | PR Newswire (Canada) | Alexion, la division des maladies rares d'AstraZeneca, et l'Alliance pharmaceutique pancanadienne (APP) parviennent à un accord au sujet de Koselugo (sélumétinib) pour le traitement des enfants atteints de neurofibromatose de type 1 (NF1) présentant de | NASDAQ:AZN | AstraZeneca PLC |
| 11/12/2024 | 16:15 | Business Wire | LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 09/12/2024 | 13:00 | Business Wire | Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer | NASDAQ:AZN | AstraZeneca PLC |
| 08/12/2024 | 17:00 | Business Wire | Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 06/12/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer | NASDAQ:AZN | AstraZeneca PLC |
| 05/12/2024 | 13:13 | Business Wire | IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer | NASDAQ:AZN | AstraZeneca PLC |
| 05/12/2024 | 12:00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
| 25/11/2024 | 13:00 | Business Wire | TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 20/11/2024 | 13:30 | Business Wire | AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US | NASDAQ:AZN | AstraZeneca PLC |
| 18/11/2024 | 22:01 | PR Newswire (US) | GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study | NASDAQ:AZN | AstraZeneca PLC |
| 13/11/2024 | 13:11 | Business Wire | アストラゼネカ、米国での研究開発と製造に35億ドルを投資 | NASDAQ:AZN | AstraZeneca PLC |
| 13/11/2024 | 13:10 | Business Wire | AstraZeneca investiert $3,5 Milliarden in R&D und Produktion in den Vereinigten Staaten | NASDAQ:AZN | AstraZeneca PLC |
| 13/11/2024 | 13:10 | Business Wire | AstraZeneca investit 3,5 milliards de dollars dans la R&D et la production aux États-Unis | NASDAQ:AZN | AstraZeneca PLC |
| 12/11/2024 | 13:00 | Business Wire | AstraZeneca’s 9M and Q3 2024 results | NASDAQ:AZN | AstraZeneca PLC |
